Aterovax’s SPLA2 Activity Test Significantly Improves Prediction Of Cardiovascular Events In Large Prospective Study
Sunday, November 15th, 2009Aterovax SA, a company developing innovative products for atherosclerosis, today announced data demonstrating that its blood test for secretory phospholipase A2 (sPLA2) activity significantly improves cardiovascular risk prediction in patients with stable coronary artery disease (CAD) over a 5 year period, independent of established risk markers, including C-reactive ...